Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Investor Day (November 2017)

100 slides from Sucampo Pharmaceuticals's investor day presentation, Nov 16, 2017

  1. Slide 1: Welcome to R&D Day

    ‘te Selene of Welcome to R&D Day November 16, 2017, New York, NY

  2. Slide 2: R&D Day

    « ¢ SUCAMPO ‘te Selene of novation SS — R&D Day Peter Greenleaf ‘Chaiman ans Chie Exec. Oricer

  3. Slide 3: Forward-Looking Statement

    Forward-Looking Statement This presentation contains “forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ ma

  4. Slide 4: Agenda for Today

    Agenda for Today Welcome Peter Greenleaf Speaker Introductions Dr Peter Kiener Familial Adenomatous Polyposis & CPP1-x/Sulindac Drs Carol Burke and Peter Kiener Niemann-Pick Type-C & VTS-270 Drs Paul Gissen, Dan Ory, and Peter Kiener Q&A Session Lunch & Discussion we

  5. Slide 5: Speaker Introductions

    peaker Introductions

  6. Slide 6: Diversified and Late-stage Portfolio

    Diversified and Late-stage Portfolio VIS-270 z ‘Pediatric Constipation 6-17 yrs. 2 = Pediatic Consipction smossys > r 1 Lubiprostone

  7. Slide 7: Carol Burke, MD

    Carol Burke, MD, FACG, FACP, FASGE, AGAF @) Director of the Section of Polyposis at the Sanford R Weiss MD Center for Hereditary Colorectal Neoplasia and Vice Chair of the Department of Gastroenterology and Hepatology at the Cleveland Clinic in Cleveland, Ohio. we

  8. Slide 8: Paul Gissen, MBCHB PhD

    Paul Gissen, MBCHB PhD Professor of Metabolic Diseases at University College of London and Consultant in Paediatric Metabolic Diseases at Great Ormond Street Hospital for Children in London, UK. $

  9. Slide 9: Dan Ory, MD

    Dan Ory, MD @) Professor of Internal Medicine, Cell Biology, and Physiology; Co-Director, Diabetic Center for Cardiovascular Disease; Alan A. and Edith L. Wolff Distinguished Professor of Medicine at the Washington University School of Medicine. we

  10. Slide 10: Familial Adenomatous Polyposis (FAP)

    e OS hada al aes. enomatous Polyposis (FAP) Carol A. Burke, MD, FACG, FACP, FASGE, AGAF

  11. Slide 11: Our Discussion Today - Familial Adenomatous Polyposis

    Our Discussion Today - Familial Adenomatous Polyposis (FAP HOW Is FAR Mieinkes + é SUCAMPO The Science of Innovation

  12. Slide 12: What Is FAP? An Introduction

    ‘te Selene of SS = What Is FAP? An Introduction

  13. Slide 13: FAP: Inheritance, Natural History, Epidemiology

    FAP: Inheritance, Natural History, Epidemiology FAP is a genetic, autosomal dominant disease caused by a mutation in the adenomatous polyposis coli (APC) gene on chromosome 5 (5q21)! FAP is a rare, life-threatening disease characterized by 100s to 1000s of colorectal adenomas & if left untreated, th

  14. Slide 14: FAP Impacts Lower Digestive Tract & Beyond

    FAP Impacts Lower Digestive Tract & Beyon Colon/rectum 100s to 1000s of colorectal adenomas Untreated, there is a 100% lifetime risk of colon cancer Stomach + ~100% of patients develop fundic gland polyps; many are dysplastic + ~2% of patients develop stomach cancer from dysplastic polyps + ~5% of p

  15. Slide 15: FAP Impacts Lower Digestive Tract & Beyond

    FAP Impacts Lower Digestive Tract & Beyond Bone and skin ~50-90% of patients develop osteomas 50% of patients develop epidermoid cysts Other organs/structures ~70-80% of FAP patients develop asymptomatic bilateral congenital hypertrophy of the retinal pigmented epithelium (CHRPE) ~11-27% of patients

  16. Slide 16: Extra-intestinal Features of FAP

    Extra-intestinal Features of FAP + Desmoid tumors (15%) + Thyroid carcinoma (2-17%) Adrenal adenoma (7-13%) + Osteomas (50-90%) + Supernumerary teeth (11-27%) + CHRPE (70-80%) + Soft tissue tumors (50%) + Lipoma, fibroma, sebaceous cysts ae + Hepatoblastoma (<2%) CHRPE of the retina (Osteomas on the

  17. Slide 17: FAP Negatively Affects Psychosocial Well-Being

    FAP Negatively Affects Psychosocial Well-Being Systematic review (1986-2007) identified studies focused on FAP impact on psychosocial well-being (Douma et ai. 2008) DY Miller et ol. 1986 Post-surgery + Reactions to diagnosis: anger, anviely, fear of death chemoprevention tal. 77%, fei guilly about p

  18. Slide 18: A Patient's Story: Living with FAP

    ‘te Selene of A Patient’s Story Living with FAP

  19. Slide 19: A Young Man's Fight Against FAP

    A Young Man’s Fight Against FAP o Grandfather, father & paternal aunt were all diagnosed with FAP t o Both his father & aunt have had their colon & duodenum removed o Father's stomach was also removed due to multiple, advanced precancerous polyps Annual 1997 2000 sigmoidoscopies + Age? + Age 12 begi

  20. Slide 20: A Young Man's Fight Against FAP

    A Young Man's Fight Against FAP © 2009 2010 + Age 21 Age 22 + Numerous rectal polyps + Arepeat sigmoidoscopy showed the rectum improved removed; experienced life- with numerous small polyps and one large polyp threatening hemorhaging «Began upper endoscopy surveillance + Some polyps as large Multipl

  21. Slide 21: A Young Man's Fight Against FAP

    A Young Man's Fight Against FAP © a He continued with esophagogastroduoden- oscopy (EGD) every 3 years Because of the risk of passing down the FAP gene, he decided not to have children Age 26 EUS demonstrated precancerous tubulovillous adenoma polyp growing up bile duct & causing intermittent blocka

  22. Slide 22: A Young Man's Fight Against FAP

    A Young Man’s Fight Against FAP 2016 + He developed + Age 28 pancreatitis, which + He died 8 months later required hospitalization in the ICU + Underwent multiple abdominal surgeries for intra-abdominal infections a)

  23. Slide 23: The Science of FAP

    The Science of FAP The Pathophysiology and Manifestations of FAP

  24. Slide 24: APC Gene Is Involved in Many Cellular Activities

    APC Gene Is Involved in Many Cellular Activities ‘Chromosomal Instability Cell Signaling Loss or deregulation Cytoskeletal Paetlon of APC may have Reorganization APC many consequences, including GENE tumorigenesis Adhesion Regtiation ‘ Migration Proliferation & Apoptosis we

  25. Slide 25: Pathways to FAP

    Pathways to FAP 1. Mutant APC leads to increased ODC & COX2 expression Polyamines (PAs) and prostaglandins are associated with increased proliferation & decreased apoptosis in tumorigenesis ODC is the first enzyme in PA biosynthesis, & COXs are involved in prostaglandin production a 7 ». Polyamine O

  26. Slide 26: How Is FAP Managed Today?

    e OS hada al aes. ———"_ Managed Today? Surveillance & Interventions in FAP

  27. Slide 27: Current Management of FAP

    Current Management of FAP The current clinical management paradigm for FAP comprises screening, surveillance, & surgery a _ = SURVEILLANCE SURGERY be a " Reps tester ar -PI + Family history + Pre- or post-surgical ious (aged 15-25 years + Personal history with associated finding colectomy, ileostomy

  28. Slide 28: FAP-Related Polyposis Requires Surgery

    FAP-Related Polyposis Requires Surgery in the Colon & Rectum + Current interventions are limited to endoscopies naan () and surgeries of the gastrointestinal tract OW + Benefit of current interventions are limited, as they only decrease polyp burden & not the underlying disease Leaving other, extra-

  29. Slide 29: Patients With FAP Undergo a Variety of Surgical Interventions

    Patients With FAP Undergo a Variety of Surgical Interventions

  30. Slide 30: Patients With FAP Undergo a Variety of Surgical Interventions

    Patients With FAP Undergo a Variety of Surgical Interventions Colectomy oN Complete removal of the colon + Attach small intestine to rectum +Desmoid tumors or oligopolyposis

  31. Slide 31: Patients With FAP Undergo a Variety of Surgical Interventions

    Patients With FAP Undergo a Variety of Surgical Interventions Proctocolectomy With Ileal Pouch +Removal of the colon/rectum + Creation of an ileal pouch «Used when patients have >500 +p CANS colon polyps, >20 rectal polyps, or A CRC

  32. Slide 32: Patients With FAP Undergo a Variety of Surgical Interventions

    Patients With FAP Undergo a Variety of Surgical Interventions Colectomy & End lleostomy +Rarely used +Patients have ileostomy bag we

  33. Slide 33: Patients With FAP Undergo a Variety of Surgical Interventions

    Patients With FAP Undergo a Variety of Surgical Interventions Duodenectomy f +Removal of the duodenum +For patients with duodenal cancer, advanced duodenal polyposis

  34. Slide 34: Current Interventions Leave Many FAP Manifestations Unaddressed

    Current Interventions Leave Many FAP Manifestations Unaddressed Skin We need to consider the whole person : 5 —~ with FAP ) liver < 5 (__B) stomach (> Duodenum © (3) Colon/Rectum 3

  35. Slide 35: CPP-1X/Sulindac Program

    e OS hada al aes. SS CPP-1X/Sulindac Program Addressing the Underlying Mechanism of FAP

  36. Slide 36: CPP-1X/Sulindac Combination of Well-Characterized Molecules

    CPP-1X/Sulindac Combination of Well-Characterized Molecules Eflornithine (DFMO) also known as CPP-1X &) + Enzyme-activated, irreversible ODC inhibitor + No approved oral form + IV formulations used for African Sleeping Sickness + Topical formulation (no systemic effect) used for hirsutism (excessive

  37. Slide 37: CPP-1X/Sulindac Reduces Polyps in Two Ways

    CPP-1X/Sulindac Reduces Polyps in 2 Ways a Polyamine “Synthesis , 4 Tumor Growth " cell proiferation Prostaglandin _— Icell death Synthesis Sulindac 3

  38. Slide 38: Strong Data Predict Success of Current FAP-310 Pivotal Trial

    Strong Data Predict Success of Current FAP-310 Pivotal Trial Preclinical studies: Clinical regression: Clinical prevention: APC Min mouse polyposis & colon Familial polyposis. Phase 2 FAP Sporadic polyposis. Phase 2/3 cancer model, showing compelling trial with CPP-1X/NSAID combo, Meyskens trial CPP

  39. Slide 39: FAP Phase 2 Proof-of-Concept Study Design

    FAP Phase 2 Trial Proof-of-Concept Stu 112 PATIENTS (evaluable data for 68) Randomized equally to 1 of 2 treatment groups 6 months of daily treatment Positive trends in all endpoints Global video assessment: Showed statistically significant regression in secondary endpoint? Is kely a stronger indica

  40. Slide 40: FAP Phase 2 Proof-of-Concept Study Results

    FAP Phase 2 Proof-of-Concept Study Results @ Results for all evaluable patients ‘COLON POLY COUNT COLON POLY? COUNT x SIZE COLON GLOBAL VIDEO ‘ONLY IN ONLY IN "ASSESSMENT LUMITED LANDMARK AREA LUMITED LANDMARK AREA or 02 0. o 0.08 02 oA 0.1 036 08 08 NSAID (CXB) ®CPP-1X/CxB

  41. Slide 41: Phase 2/3 Meyskens Trial in High-risk Polyp Formers

    Phase 2/3 Meys' © 375 PATIENTS {At high risk for polyp formation & recurrence) Prospective, randomized, placebo-controlled trial [1:1 randomization) 3 years of daily treatment ial in High-risk Polyp Formers CPP-1X (500 mg) UC Irvine, investigator. sponsored trial Sulindac (150 mg) Dr. Meyskens is As

  42. Slide 42: Phase 2/3 Meyskens Trial Efficacy Results

    Phase 2/3 Meyskens Trial Efficacy Results @ Marked reduction of polyps (adenomas) with CPP-1X/sulindac dally treatment Percentage of patients with metachronous ‘adenomatous polyps (at 3 years) so TOTAL ADENOMA <0.001 Placebo =CPP-1K/su High isk Subgroups from the Study Population o7 o7 ADVANCED ADEN

  43. Slide 43: CPP-1X/Sulindac Combination Has Extensive Clinical Activity & Minimal Toxicities

    CPP-1X/Sulindac Combination Has Extensive Clinical Activity & Minimal Toxicities + CPP-1X (eflornithine) used in many previous NCI-funded trials + Ototoxicity (hearing loss) only for specific genetic subgroup, which may be a useful genetic screening tool to predict those most likely to respond to th

  44. Slide 44: The ABCs of FAP: Essential Points to Remember

    The ABCs of FAP: Essential Points to Remember FAP is a rare, life-threatenin of 100s to 1000: © charact etized by the > Today, clinicians focus on the colon and rectum y not performed RA 5 organs “sy el > However, colectomy does not address these other disease manifestations

  45. Slide 45: Consider the Whole Person With FAP

    Consider the Whole Person With FAP + FAP is a chronic progressive disease that can be life-threatening if left untreated + The burden associated with FAP, in terms of patient medical and psychosocial needs as well as multisystem evaluation & treatment, is significant + Surgical interventions do not

  46. Slide 46: FAP-310 Phase 3 Pivotal Trial

    ‘te Selene of ———— Phase 3 Pivotal Trial

  47. Slide 47: FAP-310 Phase 3 Pivotal Trial Design

    FAP-310 Phase 3 Pivotal Trial Design Sulindac: ENDPOINT (150 mg) ‘Time to 171 PATIENTS FAP-related event’ Randomized 5 wrealment pos ae ia Over 24 months [0:12 randomization) . at any disease site ores 5 per patient with up to leant Sulindac 2-year extension (150 mg) subjects were enrolled in 11 sit

  48. Slide 48: Definition of Events in FAP-310 Trial

    Definition of “Events” in FAP-310 Trial The trial is focused on “FAP-related events” in the Gl tract, these include: + FAP-related excisional intervention (snare polypectomy or surgery) involving the colon, rectum, pouch, duodenum and/or + Clinically important events which includes progression to mo

  49. Slide 49: FAP-310 Update

    FAP-310 Update An extension allows for up to 48 months of treatment for subjects that have not had an FAP- related event Patient treatment will continue until one of the following occurs: Subject has FAP-related event or comes off study for other reasons 90 FAP-related events have occured At the dec

  50. Slide 50: Milestones to Approval

    Milestones to Approval H2 2019 A Report (FSR) FDA Approval —®© Co FDA Submission JUNE H 2017 8 2019 e oO: Applying for PRIME in EU which is analogous to Fast Track - targeted submission 4Q 2017

  51. Slide 51: Promise of Combination Therapy With CPP-1X/Sulindac

    Promise of Combination Therapy With CPP-1X/Sulindac 2) O + Inclinical trials conducted to date, combination therapy with low doses of CPP-1X/sulindac produced marked inhibition of colorectal adenomas & exceeded the effects of single agents + Moreover, combination CPP-1X/sulindac has not been associa

  52. Slide 52: Questions & Answers

    ‘te Selene of ——— Questions & Answers

  53. Slide 53: Break

    « 2 sucampo_ SS = Break

  54. Slide 54: Niemann-Pick Type C (NPC)

    e OS hada al aes. ——— Niemann-Pick Type C (NPC) Paul Gisse’

  55. Slide 55: Our Discussion Today - Niemann-Pick Type C (NPC)

    Our Discussion Today - Niemann-Pick Type C (NPC) : Inirey 10 NES 2/3 Tria) x 9 SUCAMPO ‘The Science of Innovation

  56. Slide 56: Introduction to NPC

    ? 2 sucampo_ Introduction to NPC Presentation, Clinical Features, Challenges in Diagnosis, & Future Diagnostic Approaches

  57. Slide 57: NPC is a Rare, Progressive, Neurodegenerative, & Ultimately Fatal Disease

    NPC is a Rare, Progressive, Neurodegenerative, & Ultimately Fatal Disease that can PresentatAny Age + NPC occurs with an incidence of 10.4-11.2/million/year live births!? Considered an under-estimate of the true prevalence Atypical phenotypes may not be clinically suspected High premature mortality

  58. Slide 58: What Is the Real Impact of NPC?

    e OS hada al aes. What Is the Real Impact of NPC?

  59. Slide 59: Meet Patient NC

    Meet Patient NC Baby Girl Age 5 Ags 10 + Birth- age 4 + Initial presentation NPC not recognized + Normal birth & delivery + NPC not recognized + Referred to pediatric + No difference from any + Diagnosed with speech neurologist baby or young child & language delay + Nexen + Progressive gross and fin

  60. Slide 60: Meet Patient NC

    Meet Patient NC Age Il Social impact: mood swings, “vile temper" + End of mainstream school + Speech very unclear + Abnormal eye movements Normal exams: Brain MRI VER & ERG Physical exam Repeat EEG Age 13 + 15 misdiagnosis + Epilepsy * Difficult to control + Multiple seizure types + Obesity * Diagno

  61. Slide 61: Meet Patient NC

    Meet Patient NC ©) Age 14 + 293 misdiagnosis considered + Worsening epilepsy + MRI: generalized atrophy with no focal defects + Worsening ataxia + Worsening dysphagia Normal exams: + Investigation for BATTEN’S DISEASE + Chitotriosidase & hexaosaminidase, EEG & CT of head, Metabolic screen, TFTs, LFT

  62. Slide 62: Meet Patient NC

    Meet Patient NC Diagnosed 11 Years After Initial Presentation Age 16 Age 18 + Referred to additional pediatric center - NPC suggested as « pleaaderte + Recurrent digital fracture differential diagnosis aspiration + Profound seizures + Diagnosis made by pneumonia + Gaze palsy filipin staining + Catap

  63. Slide 63: Variable Clinical Presentation Causes Diagnostic Challenge for Physicians

    Variable Clinical Presentation Causes Diagnostic Challenge for Physicians + Variable age of onset and clinical features + Visceral presentation mainly limited to neonatal + Unexplained neonatal jaundice, [hepato]splenomegaly + Resolves when survived + Neurological presentation + Psychiatric presenta

  64. Slide 64: Average Age at Diagnosis

    Average Age at Diagnosis is 10 Years Average age at diagnosis is 10.4 years os a. l fl Diagnostic delay - often not until advanced disease progression NPC Disease UK Database: Average age J of neurological Delayed ie years Ine J oft BMC Hourooay. 215515257.

  65. Slide 65: Broad Impact of Neurological & Psychiatric Features

    Broad Impact of Neurological & Psychiatric Features Time to diagnosis limited by symptomology exhibited and level of disease awareness of healthcare professionals! Neurological involvement defines the disease severity in most patients + Typically preceded by systemic signs? NEUROLOGICAL * Gelastic c

  66. Slide 66: Disease Progression is Irreversible After the Onset of Neurological Symptoms

    Disease Progression is Irreversible After the Onset of Neurological Symptoms 1 23 6 10 2 89% 4 80 6 70 (Early) Infantile (tale nen NN Cvichood Delayinmotor = [| were Gl 1 es Oo Vertical supranuclear gaze palsy _ = $

  67. Slide 67: Neurodegenerative Presentation Major Driver of Morbidity

    Neurodegenerative Presentation Major Driver of Morbidity Regardless of Age of Onset Lipid accumulation in CNS results in progressive & irreversible neuronal degradation miuvenie mAdolescent/Adutt UK Observational Cohort (N=146 patients born between 1954 & 2009) The mean (8D: range) age at neurologic

  68. Slide 68: Neurodegenerative Presentation & Sequellae are Major Causes of Mortality

    Neurodegenerative Presentation & Sequellae are Major Causes of Mortality + Mortality usually results from the neurological manifestations + Dysphagia leads to consequent aspiration pneumonia’ Aspiration pneumonia-related mortality was reported in >20% of patients, but this is likely to be an underes

  69. Slide 69: Evolving Diagnostics will Lead to Earlier Diagnosis

    Evolving Diagnostics will Lead to Earlier Diagnosis Clinical features suggestive of NPC? P) + Filipin staining of unesterified cholesterol in cultured skin fibroblasts Gold standard, but variant phenotype in 15% of cases! (higher proportion in adult cases); not 100% specific for NPC + Sequencing of

  70. Slide 70: NPC is a rare, progressive, neurodegenerative and fatal disease

    NPC is a rare, progressive, neurodegenerative and fatal disease that can present at any age A wide range of non-specific manifestations of NPC often lead to delays in diagnosis and misdiagnosis A mult-disciplinary approach necessary New cheaper, reliable, and sensitive biomarkers for NPC are now ava

  71. Slide 71: Current Management Options for NPC

    e OS hada al aes. rreent Management Options for NPC

  72. Slide 72: There Is Currently No Cure for NPC

    There Is Currently No Cure for NPC Symptomatic & palliative therapies NPC - specific therapies + Supportive therapies variably effective, + Miglustat alleviate numerous clinical problems + MOA: Oral glucosylceramide synthase inhibitor associated with NPC! : + Utilizes indirect mechanism of action fo

  73. Slide 73: No Treatments for NPC that Directly Address the Pathophysiology

    There are Currently No Treatments for NPC that Directly Address the Pathophysiology of Disease Miglustat filed to achieve its primary endpoint in patients with NPC? + In Europe, miglustat indicated for the treatment of progressive neurological manifestations in adult and paediatric patients with Nie

  74. Slide 74: Clinical Studies in NPC are Ongoing

    Clinical Studies in NPC are Ongoing ‘Study Name/Details ‘Population: Primary Outcome ‘Status: ‘Sponsor Feecne aie aeons Genetically contimed Change innrc | is Patient Diagnosed with Niemann-rick | NFCV/NPCZ: eae 2:18 remeron, | Zor5 ae | ney | “onrnine Disease Type C NCIN2412129 a 1/2 Study of Pharm

  75. Slide 75: VTS-270

    « 2 sucampo_ SS = Vais-270

  76. Slide 76: Phase 1/2 Data

    Phase 1/2 Data Animal Model Data “we

  77. Slide 77: HPβCD Treatment in a Mouse Model Showed Increased Survival

    2-Hydroxypropyl-B-Cyclodextrin (HPBCD) Treatment in a Mouse Model Showed Increased Survival + NPC] mouse model Survival’ Cerebellar pathology: 49-days? 100 4 Npel** Npc! Npel+ CD No Rx Rx2id Rx7d Percent Survival 0 25 50 75 100 125 150 175 200 25 ‘Age (days) 1 Davidson © eta PLoS Ore 2000 98851 2 LB

  78. Slide 78: HPβCD Treatment in a Cat Model Also Showed Improved Function & Survival

    HPBCD Treatment in a Cat Model Also Showed Improved Function & Survival + NPCI cat model + 24-week NPC1 mutant cats (HPBCD, miglustat, untreated) we

  79. Slide 79: Postsymptomatic Therapy Prolonged Life Span & Slowed Progression

    Postsymptomatic Therapy Prolonged Life Soan & Slowed the Progression of Neurological Dysfunction Ataxia severity at 24 weeks of age in postsymptomatic NPC cats administered + IN NPC cats administered treatment after intrathecal HPBCD from 14 weeks of age appearance of symptoms (16 weeks of age), cli

  80. Slide 80: Where Do You Dose? CNS Versus Systemic

    Where Do You Dose? CNS Versus Systemic ‘Maximum Follow-up Time (76 weeks) Koro a ~ @ Live longer a i oY tae fA, than 76 ‘ Dose Range +4000 morko* weeks up to t ' t 1 in Pivotal Trial 4years 4 @ @ 2000 mara q 1,000 matka ‘Avg. Lifespan of Npcl’/- Cats (22 weeks) 1 10 100 1,000 10,000 100,000 Total Do

  81. Slide 81: Lancet 2017: Intrathecal HPβCD in Niemann-Pick C1

  82. Slide 82: Study Methods

  83. Slide 83: No Significant Differences in Baseline Demographics & Clinical Characteristics

  84. Slide 84: Clinical Efficacy of Intrathecal HPβCD

  85. Slide 85: Clinical Efficacy of Intrathecal HPβCD

  86. Slide 86: Safety: Reported Adverse Events

  87. Slide 87: Safety: Reported Adverse Events (cont'd)

  88. Slide 88: Study Conclusions

  89. Slide 89: VTS-270 Phase 2/3 Trial

  90. Slide 90: Global Study Site Distribution

  91. Slide 91: VTS-270 Phase 2b/3 Trial Design

  92. Slide 92: Key Inclusion Criteria: Parts A and B

  93. Slide 93: Part C: Open-label Extension

  94. Slide 94: Intrathecal Access Port Device

  95. Slide 95: The VTS-270 Development Journey Continues

  96. Slide 96: Questions & Answers

  97. Slide 97: Panel Q&A

  98. Slide 98: Lunch

  99. Slide 99: Thank You!

  100. Slide 100: Slide 100

Sucampo Pharmaceuticals — Investor Day (November 2017) on 6ix